- Medical Equipment
Medacta Group Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
Medacta Group (VTX:MOVE) Full Year 2022 Results
Key Financial Results
- Revenue: €437.1m (up 20% from FY 2021).
- Net income: €46.2m (down 10% from FY 2021).
- Profit margin: 11% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses.
- EPS: €2.32 (down from €2.58 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medacta Group Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 18%.
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Switzerland.
Performance of the Swiss Medical Equipment industry.
The company's shares are up 1.8% from a week ago.
What about risks? Every company has them, and we've spotted 1 warning sign for Medacta Group you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Medacta Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally.
High growth potential with excellent balance sheet.